Home

AETHER — Deck

Aether Industries · AETHER · NSE

Aether Industries manufactures specialty chemicals and advanced intermediates in Surat, India, earning revenue through three channels: large-scale manufacturing of niche molecules, contract/exclusive manufacturing for global MNCs, and contract research services.

$12.49
Price
$166M
Market cap
$11.7M
Revenue (TTM)
33%
Operating margin TTM
Listed June 2022 at $10.22; fell to $8.41 by late 2024, then rallied 49% to $12.49 today — roughly 1.2× from IPO in under 4 years.
2 · The tension

$16M+ capex cycle bets the company on ROCE recovery from 10% to 18%+.

  • The bet. Aether tripled its asset base from $10.2M to $30.9M in three years, adding Sites 3++, 4, and 5. ROCE collapsed from 33% (FY21) to 7% (FY24) and has recovered only to 10% — half the cost of equity.
  • The payoff path. Sites 3++ and 5 begin commercial production in Q4 FY26. Site 4 runs at 49% utilization. Fixed costs are baked in — every 10pp of utilization gain adds 300–400bps of operating leverage. Q3 FY26 already showed this: 34% EBITDA margin on 44% revenue growth.
  • The timeline. If ROCE does not recover above 15% within 4 quarters of site commissioning, the capex cycle was value-destructive and the stock is overvalued by 35–40%.
Everything about this stock — the 84× P/E, the zero FCF, the bull/bear debate — reduces to one question: will the new assets earn above their cost of capital?
3 · Money picture

Revenue is accelerating at 30%+ while margins hit all-time highs — but cash generation remains negative.

$11.7M
Revenue TTM +30% YoY
33%
OPM TTM all-time high
−$4.1M
Free cash flow FY25
10%
ROCE vs 33% pre-capex

Quarterly revenue has risen from $1.4M (Q4 FY24 trough) to $3.5M (Q3 FY26) — a 169% increase in 7 quarters. The acceleration comes from CEM contract ramps (Baker Hughes at $7.1M/quarter) and LSM volume recovery (25% YoY). But cumulative FCF over FY22–FY25 is negative $15.9M, funded entirely by equity raises. The earnings-to-cash conversion ratio is 15%.

4 · What changed

The CEM pivot transforms Aether from a commodity chemistry company into a long-term contract manufacturer.

  • Mix shift. Contract/Exclusive Manufacturing rose from 26% of revenue (FY24) to 43% (Q3 FY26). Management targets 70% CRAMS+CEM revenue — turning a cyclical, price-exposed business into an annuity-like one.
  • Customer quality. Baker Hughes, Milliken, Otsuka Chemical, SEQENS, and unnamed European material science and semiconductor customers are anchor CEM partners. Contracts are 5–10 year, auto-renewing, open-book.
  • End-market diversification. Pharma + agro dropped from dominant to 45% of revenue. Oil & gas (22%) and material science (18%) are scaling. Electronic chemicals for semiconductor supply chains (Japan, Korea, Taiwan) are a new vector.
5 · Who runs this

A family with $125M of skin in the game and genuine technical DNA — but zero cash returned to shareholders.

  • Alignment. The Desai family holds 75% of equity. Ashwin Desai (74) founded Anupam Rasayan in 1976, ran it for 37 years, then started Aether in 2013. Son Dr. Aman Desai (PhD Michigan State, ex-Dow) personally leads all 50 R&D projects.
  • The gap. Zero dividends, zero buybacks since inception. Every dollar reinvested. Governance is B+: 4 family members on executive board, non-independent chair, board cannot truly challenge promoters.
  • Succession. Rohan (commercial) and Aman (technical) are operational successors. Transition is happening visibly — they lead all earnings calls.
6 · Bull and Bear

Lean Long, Wait For Confirmation — the model works but the returns inflection is unproven.

  • For. India's only scale CRAMS-to-CEM platform in non-pharma chemistry. Revenue accelerating at 30%+ — fastest in the peer set. Sites 3++/5 add 4,500+ MTPA of capacity already being filled with signed contracts.
  • For. European chemical manufacturing shutdowns create secular demand. Operating leverage from 49% Site 4 utilization is a visible margin expansion path. CEM contracts eliminate demand cyclicality.
  • Against. Never generated positive free cash flow. 15% earnings-to-cash conversion ratio. 367-day working capital cycle. At 84× P/E, the stock prices in perfection — any execution miss compresses the multiple violently.
  • Against. ROCE at 10% is half the cost of equity. PI Industries — the closest comp — trades at 34× with 23% ROCE. Aether commands a 2.5× premium on half the returns.
The business model transition is real. The financial proof is not yet in hand. Enter on the first quarter showing positive FCF and ROCE above 15%.

Watchlist to re-rate: 1) ROCE crossing 15% post-site ramp (observable FY27 H1). 2) First quarter of positive free cash flow. 3) CEM revenue share sustaining above 50%.